Biofil Chemicals & Pharmaceuticals Limited has announced the appointment of Mr. Smitesh Shah as an Additional Director in the category of Promoter Non-Executive Non-Independent Director, effective August 23, 2025. This strategic move comes as part of the company's efforts to strengthen its leadership team.

Appointment Details

The appointment of Mr. Shah, which is subject to shareholder approval at the upcoming 40th Annual General Meeting (AGM), was made upon the recommendations of the Nomination and Remuneration Committee. According to the company's disclosure, Mr. Shah will hold office until the ensuing AGM or within three months from the appointment date, whichever is earlier.

About Smitesh Shah

Mr. Smitesh Shah, aged 65, brings a wealth of experience to Biofil Chemicals & Pharmaceuticals Limited:

• Educational Background: Holds a B.Sc. degree
• Industry Experience: 45 years in the pharmaceuticals industry
• Current Directorships: Holds directorships in 6 other companies
• Family Ties: Uncle of Ketan Shah, the company's Chairman and Managing Director

Corporate Governance

The company has confirmed that Mr. Shah is not debarred from holding office by virtue of any SEBI Order or any other authority. This confirmation aligns with SEBI's requirements for listed companies to ensure the integrity of their board members.

Board Meeting Details

The Board of Directors meeting where this appointment was approved commenced at 5:00 PM and concluded at 5:45 PM on August 23, 2025.

Company Information

Biofil Chemicals & Pharmaceuticals Limited's registered office is located at 11/12, Sector E Sanwer Road, Indore-452015, Madhya Pradesh.

This appointment reflects Biofil Chemicals & Pharmaceuticals Limited's commitment to enhancing its leadership structure with experienced industry professionals. Shareholders will have the opportunity to ratify this appointment at the forthcoming Annual General Meeting.

Biofil Chemicals And Pharmaceuticals Limited, a prominent player in the chemical and pharmaceutical sector, has announced plans to sell a significant portion of its industrial land. The company's board of directors has approved a proposal to dispose of approximately 80,156 square meters of vacant industrial land located in Pithampur, Madhya Pradesh.

Key Details of the Proposed Sale

• Location: The land is situated at Plot No. 8, Sector-3, Kheda Industrial Estate, Pithampur, District Dhar, Madhya Pradesh.
• Minimum Sale Price: The company has set a minimum consideration amount of ₹16.00 crore for the property.
• Current Status: The land is presently vacant and held under leasehold rights.
• Approval Process: The sale is subject to approval from shareholders through a postal ballot and from the Madhya Pradesh Industrial Development Corporation (MPIDC).

Financial Impact

The proposed sale could have a significant impact on Biofil Chemicals And Pharmaceuticals' financial position:

Timeline and Execution

• Expected Completion: The company aims to complete the sale on or before December 31, 2025.
• Agreement Status: As of now, no formal agreement has been entered into for the disposal of the land.
• Buyer Details: The company has not yet identified a specific buyer but has stated that the prospective buyer will not be a related party or connected to the company's promoters.

Management's Decision

The decision to sell this industrial land was made during a board meeting held on August 4, 2025. The board has authorized the Whole Time Director to proceed with the postal ballot and e-voting process to obtain shareholder approval for the proposed sale.

Market Implications

This move by Biofil Chemicals And Pharmaceuticals Limited could be seen as a strategic decision to optimize its asset portfolio. The sale of this vacant industrial land may provide the company with additional capital for core business activities or debt reduction, potentially improving its financial flexibility.

Investors and market watchers will likely keep a close eye on how the company utilizes the proceeds from this sale, should it go through, and how it might impact Biofil's future growth strategies and financial health.

As the situation develops, more details are expected to emerge regarding the potential buyer and the final terms of the sale. Shareholders will play a crucial role in the decision-making process through the upcoming postal ballot.